ACOR — Acorda Therapeutics Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapValue Trap

Annual income statement for Acorda Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	192	153	129	119	118
Cost of Revenue
Gross Profit	158	119	88.3	88.2	102
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	449	231	208	127	383
Operating Profit	-257	-78.1	-79	-8.2	-265
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-274	-108	-109	-35.2	-296
Provision for Income Taxes
Net Income After Taxes	-273	-99.6	-104	-65.9	-253
Net Income Before Extraordinary Items
Net Income	-273	-99.6	-104	-65.9	-253
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-273	-99.6	-104	-65.9	-253
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-324	-147	-188	-84.6	-72.1